Ovarian Rescue/Protection from Chemotherapeutic Agents

Abstract

Background:After improved long-term survival in young women with lymphoma and leukemia undergoing chemotherapy, preservation of future fertility has been the focus of recent interest. The investigational endevors of ovarian cryopreservation await the clinical experience of in vitro maturation of thawed primordial follicles, their in vitro fertilization, and embryo transfer. Although promising, this experience is not yet available. Moreover, the risk of possible reimplantation of malignant stem cells with the thawed cryoperserved ovary has been raised after experimental animal observations. Therefore, until these innovative endeavors prove successful, and in parallel with them, we attempted to minimize the gonadotoxic effect of chemotherapy by the cotreatment with a gonadotropin-releasing hormone (GnRH) agonistic analogue to induce a temporary prepubertal milieu. Whereas inhibin-B concentrations in serum may reflect the ovarian granulosa cell compartment, inhibin-A reflects luteal function. Immunoreactive inhibin-A and -B in these patients before, during, and after gonadotoxic chemotherapy were measured.

Methods:A prospective clinical protocol was undertaken in 44 women with lymphoma, aged 15-40 years, ten with leukemia and eight undergoing cehmotherapeutic treatments for nonmalignant diseases such as systemic lupus erythematosus or other autoimmune diseases. A montly injection of depot D-TRP6-GnRH-a was administered from before the start of chemotherapy until its conclusion, up to a maximum of 6 months. A hormonal profile was taken before starting the GnRH-a/chemotherapy cotreatment, and montly therafter until the women resumed spontaneous ovulation. This group was compared with a control group of 55 women who had been treated with similar chemotherapy. Inhibin-A and -B immunoactivity was measured.

Results:Whereas all but one (40-year-old) of the surviving patients with GnRH-a/chemotherapy cotreatment group resumed spontaneous ovulation and menses within 6 months, fewer than half of the patients in the control group (chemotherapy without GnRH-A cotreatment) resumed ovarian function and regular cyclic activity (P < .05). The remaining 60% experienced premature ovarian failure (POF). Temporary increased follicle-stimulating homroe (FSH) concentrations were experienced by almost a third of the patients resuming cyclic ovarian function, suggesting a reversible ovarian damage in a larger proportion of women than those experiencing POF. Inhibin-A and -B decreased during GnRH-a/chemotherapy cotreatment but increased to normal levels in patients who resumed regular ovarian cyclicity and/or spontaneously conceived, compared with low levels in those who developed POF.

Conclusions:If these preliminary data are consistent in a larger group of patients, inhibin-A or -B concentrations may serve as prognostic factors to predict the resumption of ovarian function, in addition to the levels of FSH, luteinizing hormone, and estradiol. GnRH-a cotreatment should be considered for every woman of reproductive age who receives chemotherapy, in addition to assisted reproductive technology and the investigational attempts of ovarian cryopreservation for future in vitro maturation.

Keywords

Inhibin-A and -B gonadotoxicity premature ovarian failure hypergonadotropic amenorrhea chemotherapy GnRH-a

Get full access to this article

View all access options for this article.

References

Blumenfeld Z

Haim N

. Prevention of gonadal damage during cytotoxic therapy. Ann Med1997;29:199-206.

Gosden RG

Rutherford AJ

Norfolk DR

. Debate: Ovarian banking for cancer patients. Transmission of malignant cells in ovarian grafts. Hum Reprod1997;12:403-403.

Shaw J

Trounson A

. Oncological implications in the replacement of ovarian tissue. Hum Reprod1997;12:403-405.

Glaser SL

. Reproductive factors in Hodgkin disease in women: A review. Am J Epidemiol1994;139:237-246.

Ataya K

Moghissi K

. Chemotherapy induced premature ovarian failure: Medications and prevention. Steroids1989;54:607-626.

Magrath I

. Limiting therapy for limited childhood non-Hodgkin's lymphoma. N Engl J Med1997;337:1304-1306.

De Vita VT

Serpick AA

Carbone PP

. Combination chemotherapy in the treatment of advanced Hodgkin disease. Ann Intern Med1970;73:881-886.

DeVita VT, Jr

Simon RM

Hubbard SM

, et al. Curability of advanced Hodgkin's disease with chemotherapy. Ann Intern Med1980;92:587-595.

Blumenfeld Z

Aviv I

Ritter M

Rowe JM

. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig1999;6:229-239.

10.

Chapman RM

Sutcliffe SB

Malpas JS

. Cytotoxic induced ovarian failure in women with Hodgkin's disease. I. Hormonal function. JAMA1979;242:1877-1881.

11.

Kreuser ED

Xirus N

Hetzel WD

Himpel A

. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy of Hodgkin's disease. J Cancer Res Clin Oncol1987;113:260-266.

12.

Rivkees SA

Crawford JD

. The relationship of gonadal damage. JAMA1988;259:2123-2125.

13.

Shafet SM

Beardwell CG

Morris PH

Pearson D

Orrell DH

. Ovarian failure following abdominal irradiation in childhood. Br J Cancer1976;33:655-658.

14.

Ataya KM

McKanna JA

Weintraub AM

Clark MR

LeMaire WJ

. Prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res1985;45:3651-3656.

15.

Bines J

Oleske DM

Cobleigh MA

. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol1996;14:1718-1729.

16.

Muller U

Stahel RA

. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin lymphoma. Am Oncol1993;4:399-402.

17.

Sanders JE

Buckner CD

Amos D

, et al. Ovarian function following marrow transplantation for aplastic anaemia or leukaemia. J Clin Oncol1988;6:813-817.

18.

Trounson AO

Bongso A

. Fertilization and development in humans. Curr Topics Dev Biol1996;32:59-101.

19.

Vincent C

Johnson MH

. Cooling, cryoprotectants and the cytoskeleton of the mammalian oocyte. Oxford Rev Reprod Biol1992;14:72-100.

20.

Barnes FL

Kausche A

Tiglias J

Wood C

Wilton L

Tronnson A

. Production of embryos from in-vitro matured primary human oocytes. Fertil Steril1996;65:1151-1156.

21.

Apperly JF

Reddy N

. Mechanism and Management of gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev1995;9:93-116.

22.

Theriault RL

Sellin RV

. Estrogen-replacement therapy in younger women with breast cancer. Monogr Natl Cancer Inst1994;16:149-152.

23.

Early Breast Cancer Trialists' Collaborative Group

. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 occurrences and 24,000 deaths among 75,000 women. Lancet1992;339:1-15, 71-85.

24.

Rose DP

Davis TE

. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet1977;i:1174-1176.

25.

Gosden RG

. Transplantation of ovaries and testes. In:

Edwards RG

, ed. Fetal tissue transplants in medicine. Cambridge: Cambridge University Press, 1992:253-279.

26.

Shaw JM

Bowels J

Koopman P

. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to the graft recipient. Hum Reprod1996;11:1668-1673.

27.

Blumenfeld Z

Avivi I

Linn S

Epelbaum R

Ben-Shahar M

Haim N

. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod1996;11:1620-1626.

28.

Blumenfeld Z

Ritter M

Shariki K

Haim N

. Inhibin-A concentrations in sera of young women during and following chemotherapy for lymphoma: Correlation with ovarian toxicity. Presented at the 44th Annual Meeting of the Society for Gynecologic Investigation, San Diego, CA, March 20-22, 1997. J Soc Gyn Investig (Suppl.). Am J Reprod Immunol 1998;39:33-40.

29.

Groome NP

O'Brien M

. Two-site immunoassays for inhibin and its subunits: Further applications of synthetic peptide approach. J Immunol Methods1993;165:167-176.

30.

Ortin TT

Shoshlak CA

Donaldson SS

. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: The Stanford experience. Int J Radiol Oncol Biol Phys1990;19:873-880.

31.

Ataya K

Rao LV

Laurence E

Kimmel R

. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod1995;52:365-372.

32.

Krause W

Pfluger KH

. Treatment with the gonadotropin-releasing hormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia1989;21:265-270.

33.

Byrne J

Mulvihill JJ

Myers MH

Connelly RR

Naughton MD

Krauss MR

, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med1987;317:1315-1321.

34.

Jarrell JF

McMahon A

Barr RD

Young Lai EV

. The agonist (d-leu-6, des-gly-10)-LHRH-ethylamide does not protect the fecundity of rats exposed to high dose unilateral ovarian irradiation. Reprod Toxicol1991;5:385-388.

35.

Sobrinho LG

Levine RA

DeConti RC

. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol1971;109:135-139.

36.

Benson K

Hartz AJ

. A comparison of observational studies and randomized, controlled trials. N Engl J Med2000;342:1878-1886.

37.

Concato J

Shah N

Horwitz RI

. Randomized, controlled trials, observational studies and the hierarchy of research designs. N Engl J Med2000;342:1887-1892.

38.

Blumenfeld Z

Shapiro D

Shteinberg M

Avivi I

Nahir M

. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus2000;9:1-5.